Enhance Portfolio & BroadenTherapeutic Focus

Focused and disciplined In-licensing and R&D strategy

• Unmet medical need

• Leverage current R&D expertise / experience

  • Pulmonology (Alpha-1-Antitrypsin)
  • Sepsis (BPI/Neuprex, Ceprotin)
  • Other biologics in discovery

• Leverage manufacturing expertise and future available capacity

New Therapeutic Areas

Previous slide

Next slide

Back to first slide

View graphic version